U.S. Mortgage Finance Stock News

Wondering if Aptiv's current share price reflects its true worth, or if the recent swings are masking a clearer story about value. Aptiv closed at US$57.11, with returns of a 5.2% decline over 7 days, a 1.9% decline over 30 days, a 27.2% decline year to date, but a 10.3% gain over the past year, which can leave the stock looking quite different depending on the time frame you focus on. Those mixed returns sit against a backdrop of ongoing attention on Aptiv as an auto components supplier, as...

Geospace Technologies (GEOS) opened Q1 2026 with revenue of US$25.6 million and a basic EPS loss of US$0.76, alongside a trailing twelve month basic EPS loss of US$2.17 on revenue of US$99.2 million. Over recent quarters the company has reported revenue between US$18.0 million and US$37.2 million, while EPS has ranged from a profit of US$0.66 per share in Q1 2025 to several loss-making quarters since. For investors, that mix of fluctuating topline and persistent losses keeps the attention on...

Janus Henderson Group (JHG) closed out FY 2025 with fourth quarter revenue of US$1.1 billion and basic EPS of US$2.64, capping a trailing twelve month net income of US$798.3 million on basic EPS of US$5.25. Over the past year, total revenue has moved from US$2.5 billion on trailing basic EPS of US$2.57 to US$3.1 billion on trailing basic EPS of US$5.25, alongside an improvement in net profit margin from 16.1% to 25.8%. This puts earnings quality front and center for investors assessing the...

If you are wondering whether Par Pacific Holdings at US$62.25 is still attractively priced after a strong run, the next sections will walk through what the current market price may be implying about the stock. The share price has pulled back with a 5.2% decline over the last week and a 3.7% decline over the last month, even though the year to date return stands at 73.8% and the 1 year return at 255.1%. Recent news coverage has focused on Par Pacific Holdings as an oil and gas refiner and...

Assertio Holdings (ASRT) closed out FY 2025 with Q4 revenue of US$13.5 million and basic EPS of a US$1.86 loss, alongside a trailing twelve month revenue base of US$118.7 million and basic EPS of a US$4.74 loss. Over the past year, quarterly revenue has moved between US$26.5 million and US$49.5 million, while quarterly basic EPS has ranged from a US$2.56 loss to US$1.78, leaving investors focused on how these shifts are feeding through to underlying margins. See our full analysis for Assertio...

SIFCO Industries (SIF) opened Q1 2026 with total revenue of US$24.0 million and net income of US$1.8 million, translating to basic EPS of US$0.29 for the quarter. The company has seen quarterly revenue move from US$21.7 million in Q4 2024 to US$20.9 million in Q1 2025 and then to US$24.0 million in Q1 2026. Basic EPS shifted from a loss of US$0.25 in Q4 2024 and US$0.40 in Q1 2025 to a profit of US$0.29 in the latest period. This sets up an earnings season in which investors are likely to...

Token Cat (TC) has just posted its H1 2025 numbers, with revenue of C¥19.8 million and a net income loss of C¥0.7 million, translating to basic EPS of C¥5.74 loss per share, while trailing 12 month figures show revenue of C¥36.6 million and a net loss of C¥148.0 million, or C¥1,200.49 loss per share. Over recent half year periods the company has seen revenue move from C¥32.3 million in H1 2024 to C¥16.9 million in H2 2024 and then to C¥19.8 million in H1 2025. Over the same periods, EPS...

Afya (NasdaqGS:AFYA) reports revenue and EBITDA growth, highlighting resilient financial performance in its latest earnings update. The Medical Practice Solutions segment faces pressure from declining active payers and stronger competition from AI driven tools. These developments point to a mixed picture for Afya, with solid headline results and emerging challenges beneath the surface. Afya operates across medical education and healthcare services in Brazil, and its latest report underlines...

For readers considering whether Sprouts Farmers Market at around US$80.99 still represents good value, or whether the key part of the move has already occurred, this article outlines what the current price may be implying. The stock has been choppy recently, with a 1% slip over the last week, a 5% gain over the last month, a modest 0.4% return year to date, and a 48.8% decline over the past year. This sits alongside a 120.3% return over three years and 212.8% over five years. These moves...

If you are wondering whether Arrowhead Pharmaceuticals at around US$77.95 is still offering value or has already run too far, this breakdown is designed to help you frame that question clearly. The stock has returned 6.1% over the past week, 27.4% over the last 30 days, 15.0% year to date, and 488.3% over the past year, which naturally raises questions about how much of the story is already priced in. Recent coverage has focused on Arrowhead Pharmaceuticals' progress in RNA interference...

If you are trying to work out whether LyondellBasell Industries' current share price reflects its underlying value, the recent moves in the stock give you plenty to think about. The stock closed at US$71.51, with a 4.1% decline over the past week and a 10.9% decline over the past month, yet it has returned 61.1% year to date and 36.5% over the last year. Recent coverage around LyondellBasell has focused on its position within the broader chemicals sector and how investors are weighing...

Navan (NasdaqGS:NAVN) has secured Criteo and Schindler as new enterprise clients for its AI-powered corporate travel platform. The agreements cover multi country travel programs and use Navan’s unified system for booking, policy compliance, and traveler support. Both clients are using Navan’s tools for operational efficiency, sustainability tracking, and user satisfaction across their global workforces. For investors watching corporate travel and expense software, Navan sits at the...

Legence (NasdaqGS:LGN) reported strong quarterly results, supported by organic growth across the business. The Installation & Maintenance segment delivered major outperformance within the period. Recent acquisitions were integrated into the business, contributing to current operations. Management raised 2026 guidance, signaling higher internal expectations for future performance. Legence, listed as NasdaqGS:LGN, focuses on installation and maintenance services, an area that can be closely...

Wondering whether FTAI Aviation stock still offers value at its current price, or if most of the opportunity is already reflected in the share price. The stock last closed at US$272.54, with returns of 9.2% over 7 days, 13.1% over 30 days, 29.6% year to date, 149.9% over 1 year, and a very large 3 year and 5 year return. Recent coverage has focused on how this rapid share price performance has put more attention on what investors are paying for each dollar of future cash flow and asset...

Wondering if Revolution Medicines at around US$142.51 is still offering value after its strong run, or if you are late to the story? This article focuses squarely on what the current price could mean for you as a shareholder. The stock has seen a 1.1% decline over the last 7 days, but that comes after strong gains of 48.0% over 30 days, 80.3% year to date, 240.0% over 1 year and a very large 3 year return of 456.2% and 5 year return of 363.6%. Recent headlines around Revolution Medicines...

Wondering if CubeSmart at US$40.25 is offering good value right now, or if the easy gains are already behind it. The stock has been relatively steady over the last year with a 0.1% return, but the 8.1% return over 30 days and 13.7% return year to date show that sentiment around the shares has shifted recently. Recent trading moves have picked up as investors reassess listed real estate and storage focused stocks more broadly, with CubeSmart part of that conversation. This has put more...

CVB Financial (NasdaqGS:CVBF) has completed its acquisition of Heritage Commerce Corp, creating a larger combined bank. The company has released pro forma financials for 2025 for the merged entity, giving investors a first look at the combined profile. This transaction marks a meaningful change in CVB Financial’s scale and business mix compared with its prior standalone position. CVB Financial, trading at $20.51, now reflects a business that is materially different from the one behind its...

Investors may be wondering whether RingCentral's current share price reflects its true worth, or if the recent price action has left it mispriced in either direction. The stock last closed at US$45.39, with returns of 12.9% over 7 days, 19.5% over 30 days, 64.5% year to date, 70.5% over 1 year, 58.2% over 3 years, and an 80.9% decline over 5 years. This presents a mixed picture of strong rebounds alongside longer term losses. Recent coverage has focused on RingCentral's position as a...

If you are wondering whether PTC at around US$147.65 is priced attractively, this article walks through what the current valuation signals might mean for you. The stock has seen an 8.3% move over the last 7 days and 2.6% over the past month, but is still showing a 13.2% decline year to date and a 10.4% decline over the last year, which may catch the eye of investors weighing potential opportunity against recent sentiment. Recent coverage of PTC has focused on its role as a US software...

Wondering if Scholar Rock Holding at around US$46.45 is giving you fair value or a potential opportunity? This article walks through the key numbers in plain language so you can judge for yourself. The stock has seen mixed recent returns, with a 0.3% decline over the last 7 days and a 6.9% decline over the last month, alongside gains of 8.5% year to date, 49.9% over 1 year and a very large 3 year return, plus a 63.3% gain over 5 years. These moves have come as investors weigh ongoing...

Investors may be wondering whether Evercore, at around US$331 per share, still offers value or whether most of the easy gains are already behind it. The stock has delivered a 3.1% move over the last week and 7.9% over the past month, while year to date it is at a 5.7% decline against a 54.6% return over the last year, a 225.1% return over three years, and 154.1% over five years. Recent coverage has focused on Evercore's role in major advisory mandates and its position within capital markets...

Wondering if Hercules Capital's share price really reflects what you are getting for your money? This breakdown walks through what the current market price might be missing or already pricing in. Recently, the stock closed at US$16.40, with returns of 2.2% over 7 days, 8.5% over 30 days, 4.0% over 1 year and 67.6% over both 3 and 5 years, while the year to date return sits at a 13.0% decline. These moves sit against a backdrop of ongoing interest in income focused business development...

Praxis Precision Medicines (NasdaqGS:PRAX) reported that the FDA accepted New Drug Applications for ulixacaltamide and relutrigine. The company is preparing for potential U.S. launches following these NDA acceptances. Praxis also highlighted clinical progress for elsunersen, adding to momentum across its late-stage pipeline. For readers tracking central nervous system drug developers, Praxis sits at an important point in its evolution, with ulixacaltamide and relutrigine moving into formal...

If you are wondering whether Gulfport Energy, at a last close of US$178.80, is attractively priced or if the easy gains are behind it, this article breaks down what the current share price might be implying about the stock's value. The stock has seen a 7.1% decline over the last week, a 13.9% decline over the last month, and a 13.3% decline year to date, set against a 94.6% return over the last 3 years and a 5.0% decline over the last year. Recent coverage has focused on Gulfport Energy's...